Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.39 |
| ▸ | SRC | P12931 | 7/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | WEE1 | P30291 | 3/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.38 |
| ▸ | ABL1 | P00519 | 5/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035484 | 0.90 | CDK4 (0.43) | CDK4CDK6FGFR1FGFR2FGFR4 | |
| SCHEMBL15041298 | 0.88 | CDK4 (0.43) | CDK4CDK6TNK2FGFR1SRC | |
| SCHEMBL15035251 | 0.87 | CDK4 (0.43) | CDK4CDK6RIPK2ACVR1NOD2 | |
| SCHEMBL15035272 | 0.82 | FGFR1 (0.57) | CDK4CDK6TNK2FGFR1SRC | |
| SCHEMBL15035258 | 0.82 | PAK3 (0.57) | CDK4CDK6TNK2SRCWEE1 | |
| SCHEMBL15035249 | 0.81 | CDK4 (0.41) | CDK4CDK6RIPK2ACVR1NOD2 | |
| SCHEMBL15035341 | 0.80 | RIPK2 (0.41) | CDK4CDK6RIPK2NOD2TNK2 | |
| SCHEMBL15035255 | 0.79 | PAK1 (0.42) | RIPK2NOD2TNK2 | |
| SCHEMBL15035250 | 0.78 | TNK2 (0.43) | CDK4CDK6RIPK2ACVR1NOD2 | |
| SCHEMBL15035257 | 0.78 | CDK4 (0.42) | CDK4CDK6RIPK2ACVR1NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2011156775-A2 | 8-(2'-HETEROCYCYL)PYRIDO[2.3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CDK4 404/4885CDK6 435/4885RIPK2 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.